On September 10, 2021 BioEclipse Therapeutics, a clinical-stage immuno-oncology company focused on developing innovative therapeutics based on its patented natural killer T-cell (NKT)/oncolytic virus technology platform, reported that Pamela Reilly Contag, Ph.D., Founder and CEO, will present at the H.C. Wainwright Annual Global Healthcare Conference taking place virtually September 13-15, 2021 (Press release, BioEclipse Therapeutics, SEP 10, 2021, View Source [SID1234587562]). The prerecorded presentation will be available online starting at 7 a.m. ET on September 13, 2021 and can be accessed via the conference’s virtual platform by registered conference attendees.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Dr. Contag and members of the BioEclipse management team are also hosting one-on-one meetings with registered investors and biopharmaceutical industry executives.
During her presentation, Dr. Contag will provide an overview of BioEclipse’s business and highlight the company’s proprietary technology platform and the role it plays in the development of a new class of immune therapeutics. These therapies pair the tumor-locating ability of cytokine-induced killer (CIK) cells with the power of an oncolytic virus that selectively infects and kills malignant cells to create a multi-modal therapy that overcomes the limitations that have previously hobbled the efficacy of cellular and oncolytic viral therapies.
Details of the presentation are as follows:
Event:
H.C. Wainwright Annual Global Healthcare Conference
Date:
September 13-15, 2021
Time:
Presentation available online beginning at 7 a.m. ET, September 13, 2021
Registration: